About GtreeBNT
GtreeBNT is a company based in Seongnam-si (South Korea) founded in 2000 was acquired by HLB in September 2021. The company has 95 employees as of December 31, 2024. GtreeBNT operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Revolution Medicines and MiRagen, among others.
- Headquarter Seongnam-si, South Korea
- Employees 95 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
- Legal Name Hlb Therapeutics Co., Ltd.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of GtreeBNT
GtreeBNT is a publicly listed company on the KRX with ticker symbol 115450 in South Korea, operating in the Distribution services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Funding Insights of GtreeBNT
- Total Funding Total Funding
- Total Rounds 1
- Last Round Last Round
- First Round First Round
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May, 2015 | Amount | Post-IPO - GtreeBNT | Valuation |
investors |
Investors in GtreeBNT
GtreeBNT has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include HLB and E&Investment.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location | |
|
Marine composite materials are manufactured for industry applications.
|
Founded Year | Domain | Location |
Investments & Acquisitions by GtreeBNT
Financial Statements - GtreeBNT
Gtreebnt Comparisons
Competitors of GtreeBNT
GtreeBNT operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Revolution Medicines and MiRagen, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Cancer therapies are developed using selective pathway inhibitors.
|
|
| domain | founded_year | HQ Location |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| domain | founded_year | HQ Location |
Therapeutics for cancer and rare diseases are developed.
|
Frequently Asked Questions about GtreeBNT
GtreeBNT was founded in 2000 and raised its 1st funding round 15 years after it was founded.
GtreeBNT is headquartered in Seongnam-si, South Korea. It is registered at Seongnam-si, Gyeonggi-do, South Korea.
Yang Won Suk is the current CEO of GtreeBNT.
As of Dec 31, 2024, the latest employee count at GtreeBNT is 95.
Annual revenue of GtreeBNT is $37.24M as on Dec 31, 2024.
GtreeBNT was established in 2000 in Seongnam-si, South Korea, within the biotechnology sector. Focus is placed on developing treatments for brain cancer, specifically glioblastomas. The lead candidate, OKN-007, is advanced in phase Ib clinical trials and has obtained orphan drug designation from the USFDA. This therapy is designed to protect neural tissue and reduce necrosis in brain cells through the removal of reactive oxygen species and inhibition of endoglucosamine-6-sulfatase.
GtreeBNT's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
Yes, GtreeBNT is publicly traded on KRX under the ticker symbol 115450.
GtreeBNT has 2 investors. Key investors include HLB, and E&Investment.
The ticker symbol of GtreeBNT is 115450 on KRX.